Molecule Generation

AI-driven generation of novel molecules to accelerate and improve drug discovery processes

Business impact

• Time to market — Shortens drug development cycles by generating candidate molecules faster
• R&D efficiency — Improves resource utilization by focusing on promising molecular candidates
• Cost reduction — Lowers screening and synthesis costs through virtual molecule generation
• Hit identification rate — Increases success rate by producing biologically active hit-like molecules
• Clinical trial success rate — Enhances candidate quality leading to better clinical outcomes
• Modeling accuracy — Improves prediction of molecular interactions for better candidate selection
• Drug discovery success rate — Boosts overall success by integrating AI-driven molecule design

Data requirements

• Chemical structure databases (Structured) — Provide molecular graphs and properties for model training
• Biological assay results (Numeric) — Offer activity data to validate generated molecules
• Protein target structures (Image) — Enable modeling of molecule-target interactions
• Scientific literature and patents (Text) — Supply textual knowledge for contextual molecule design
• Experimental screening data (Numeric) — Support iterative feedback for model refinement

AI methods and techniques

• Generative AI — Create novel molecular structures with desired properties using deep learning
• Predictive AI — Estimate biological activity and binding affinity of generated molecules
• Symbolic AI — Incorporate chemical rules and constraints to ensure valid molecule generation

AI models and model families

DiGress, MolRNN, GraphINVENT, AlphaFold 2.3, Foundation Models, Graph Neural Networks, Generative Flow Networks

Industries

Real-world evidence

7 documented case studies on record.

Companies using this: CHARM Therapeutics, Global Health Drug Discovery Institute GHDDI, Google, Insilico Medicine, Mc Master University, University College London, Valence Labs.